Shares of clinical-stage genetic medicine provider Wave Life Sciences (NASDAQ:WVE) are soaring higher today after the company announced a key collaboration with GSK (NYSE:GSK) with a focus on Oligonucleotide therapeutics.
The four-year collaboration will include Wave’s WVE-006 RNA editing program which targets alpha-1 antitrypsin deficiency. Further, a key component of the collaboration discovery which will enable the advancement of GSK’s eight programs and Wave’s three programs.
Under the agreement, Wave gets $170 million in the combination of an upfront payment and an equity investment. Additionally, the company also stands to make $225 million in development and launch milestones and $300 million in sales milestones.
Analysts currently have a Moderate Buy consensus rating on the stock alongside an average price target of $7. Shares of the company have now soared nearly 112% over the past six months.
Read full Disclosure
